<?xml version="1.0" encoding="UTF-8"?>
<list list-type="alpha-lower">
 <list-item>
  <p>Residents or staff developing ILI while on prophylactic doses of an antiviral agent need to be considered for treatment doses if influenza is diagnosed or considered likely.</p>
 </list-item>
 <list-item>
  <p>Residents or staff receiving chemoprophylaxis who develop ILI should be assessed and tested to determine the cause of their illness, which may be due to the current virus, another viral agent or an oseltamivir- (or zanamavir)-resistant influenza virus.</p>
 </list-item>
</list>
